ONCS - OncoSec Medical Incorporated

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

OncoSec Medical Incorporated

24 North Main Street
Pennington, NJ 08534
United States
855-662-6732
http://oncosec.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees33

Key Executives

NameTitlePayExercisedYear Born
Dr. Avtar S. DhillonCo-Founder & Chairman170kN/A1962
Mr. Daniel J. O'Connor J.D.Pres, CEO & Director372.58kN/A1964
Mr. Punit S. Dhillon B.A., BACo-Founder & Director1.66MN/A1980
Ms. Sara M. BonsteinCFO, COO & Company Sec.81.73kN/A1981
Dr. Christopher G. Twitty Ph.D.Chief Scientific OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. The company is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in the Phase IIb clinical trials (PISCES/KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in the Phase II clinical trials (OMS-141/KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, it undertakes the phase II monotherapy biomarker study in patients with advanced or metastatic TNBC. Further, the company has completed Phase I neoadjuvant clinical trial of ImmunoPulse IL-12 in combination with an anti-PD-1 in surgically resectable melanoma. Additionally, it is developing new DNA-encoded therapeutic candidates and tumor indications. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the PISCES/KEYNOTE-695 and OMS-141/KEYNOTE-890 studies; and a collaboration with the GOG Foundation, Inc. to conduct a registration-enabled study of tavokinogene telseplasmid in women with recurrent/persistent cervical cancer. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.

Corporate Governance

OncoSec Medical Incorporated’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.